Sigma Planning Corp Sells 7,228 Shares of Moderna, Inc. (NASDAQ:MRNA)

Sigma Planning Corp reduced its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 72.2% during the 4th quarter, HoldingsChannel.com reports. The firm owned 2,777 shares of the company’s stock after selling 7,228 shares during the quarter. Sigma Planning Corp’s holdings in Moderna were worth $276,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Allworth Financial LP grew its holdings in shares of Moderna by 6.5% during the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the last quarter. TIAA Trust National Association grew its holdings in shares of Moderna by 2.3% during the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after purchasing an additional 102 shares during the last quarter. Sound Income Strategies LLC grew its holdings in shares of Moderna by 17.8% during the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after purchasing an additional 115 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Moderna by 18.8% during the third quarter. IFP Advisors Inc now owns 834 shares of the company’s stock worth $86,000 after purchasing an additional 132 shares during the last quarter. Finally, Bay Colony Advisory Group Inc d b a Bay Colony Advisors lifted its stake in shares of Moderna by 6.5% in the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock worth $245,000 after acquiring an additional 151 shares during the period. 75.33% of the stock is currently owned by institutional investors.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now directly owns 8,557 shares of the company’s stock, valued at $809,235.49. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, insider Shannon Thyme Klinger sold 670 shares of the company’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the completion of the sale, the insider now owns 8,557 shares in the company, valued at $809,235.49. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, March 13th. The stock was sold at an average price of $108.54, for a total value of $1,628,100.00. Following the sale, the director now owns 2,131,931 shares of the company’s stock, valued at approximately $231,399,790.74. The disclosure for this sale can be found here. Insiders have sold 124,954 shares of company stock valued at $13,158,776 over the last ninety days. 15.70% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the company. Jefferies Financial Group reaffirmed a “buy” rating and issued a $125.00 price objective on shares of Moderna in a research note on Tuesday, April 9th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. HSBC reaffirmed a “reduce” rating and issued a $86.00 price objective (up from $75.00) on shares of Moderna in a research note on Monday, February 26th. Canaccord Genuity Group lifted their price objective on Moderna from $82.00 to $91.00 and gave the stock a “hold” rating in a research note on Friday, February 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Moderna in a research note on Thursday, April 11th. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the stock. According to MarketBeat, Moderna currently has an average rating of “Hold” and a consensus price target of $126.49.

Moderna Stock Up 1.7 %

Shares of NASDAQ:MRNA opened at $107.97 on Friday. The company has a quick ratio of 3.36, a current ratio of 3.42 and a debt-to-equity ratio of 0.04. Moderna, Inc. has a twelve month low of $62.55 and a twelve month high of $142.79. The stock’s 50 day moving average is $102.54 and its 200-day moving average is $93.70.

Moderna (NASDAQ:MRNA) last issued its earnings results on Thursday, February 22nd. The company reported $0.55 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative return on equity of 10.23% and a negative net margin of 68.84%. The company had revenue of $2.80 billion for the quarter, compared to analyst estimates of $2.53 billion. During the same period in the prior year, the firm earned $3.61 earnings per share. Moderna’s revenue for the quarter was down 44.9% on a year-over-year basis. As a group, equities research analysts predict that Moderna, Inc. will post -7.51 EPS for the current fiscal year.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.